Inclusion Criteria:

          1. Males and females greater than or equal to 18 years of age

          2. Life expectancy of at least 3 months

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1

          4. For Part A1: Diagnosis of histopathologically confirmed B-cell hematological
             malignancy (as per the World Health Organization [WHO] 2016 classification; Swedow
             2016); eligible subtypes include follicular lymphoma, MZL, DLBCL, mantle cell
             lymphoma, lymphoplasmacytic lymphoma, and WM/LPL without the urgent need for treatment
             hyperviscosity.

             For Part A2: Diagnosis of histopathologically confirmed B-cell NHL, as per the WHO
             2016 classification (Swerdlow et al. 2016). Eligible NHL subtypes include follicular
             lymphoma, MZL, mantle cell lymphoma, DLBCL(including extranodal lymphomas of leg-,
             testicular-, or NOS type), CLL/SLL, primary or secondary CNS lymphoma and Waldenström
             macroglobulinemia / LPL.

             For Part B: Diagnosis of histopathologically confirmed B-cell NHLs, including
             applicable confirmation as per the WHO 2016 classification (Swerdlow et al. 2016):

               -  Cohort 1: Marginal zone lymphoma

               -  Cohort 2: ABC-DLBCL, or extranodal subtypes: Leg-, testicular-, or NOS-type. The
                  population will be enriched for MYD88 L265P mutations. As this occurs more
                  frequently in the ABC-DLBCL(activated B-cell (Hans et al. 2004) subtype, all
                  patients with this subtype qualify for enrollment. If the MYD88 mutation status
                  is unknown at baseline, the lymphoma will be tested for MYD88 mutations.

               -  Cohort 3: Primary CNS Lymphoma (PCNSL) only. If the MYD88 mutation status is
                  unknown at baseline, the lymphoma will be tested for MYD88 mutations.

               -  Cohort 4: Patients receiving ibrutinib monotherapy who have developed adaptive,
                  secondary resistance. Indications include:

                    -  MCL, MZL, CLL/SLL, or WM/LPL

                    -  Indications for which ibrutinib is NCCN-listed (e.g., PCNSL)

                    -  Patients with NHL and known myddosome mutations

                    -  Patients may be candidates for maintaining ibrutinib while CA-4948 will be
                       added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks
                       is acceptable.

          5. Relapsed or refractory measurable disease for which patients are ineligible for or
             have exhausted standard therapeutic options that would be considered standard of care

        Exclusion Criteria:

          1. Active central nervous system (CNS) involvement other than PCNSL (Part A2 or B) or
             secondary CNS lymphoma (Part B only).

          2. Radiotherapy delivered to non-target lesions involving >25% of bone marrow within one
             week prior to starting study treatment or delivered to target lesions that will be
             followed on the study (NOTE: prior sites of radiation will be recorded)

          3. Any prior anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy,
             etc., received within 14 days prior to start of study treatment (with the exception of
             ibrutinib for Parts A2 and B, which may be continued as part of this study without
             interruption)

          4. Current or planned glucocorticoid therapy, with the following exceptions:

               1. Doses ≤ 10 mg/day prednisolone or equivalent is allowed, provided that the
                  steroid dose has been stable or tapering for at least 14 days prior to the first
                  dose of study treatment

               2. Inhaled, intranasal, intraarticular and topical steroids are permitted

          5. Use of any investigational agent within 21 days or 5 half-lives, whichever is shorter,
             prior to start of study treatment

          6. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy,
             with the exception of alopecia, that has not resolved to Grade ≤ 1 within 7 days prior
             to start of study treatment unless approved by the Medical Monitor

          7. Known allergy or hypersensitivity to any component of the formulation of CA-4948 (or
             ibrutinib for entry into Parts A2 or B) used in this study

          8. B-cell NHL of the following subtypes:

               1. Burkitt lymphoma

               2. Lymphoblastic lymphoma or leukemia

               3. Post-transplantation lymphoproliferative disorder

               4. Known primary mediastinal, ocular, or epidural, DLBCL

               5. WM patients requiring urgent treatment due to hyperviscosity